Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > VNDA Vanda Pharmaceuticals > Company Executives
VNDA Vanda Pharmaceuticals
Post Mkt Price
NamePositionSalaryService DateEducationAgeGenderUpdated
Dr. Mihael Hristos Polymeropoulos,M.D.Chairman of the Board, President and Chief Executive Officer6.19M----62male04/25/2022
Mr. Joakim WijkstromSenior Vice President and Chief Marketing Officer1.85M----56male04/25/2022
Mr. Kevin MoranSenior Vice President, Principal Accounting Officer, Chief Financial Officer and Treasurer1.97M----38male04/25/2022
Mr. Timothy WilliamsSenior Vice President, General Counsel and Secretary2.03M----46male04/25/2022
Mr. Gunther BirznieksSenior Vice President, Business Development2.00M----53male04/25/2022
Mr. Richard W. DuganIndependent Director253.24K----80male04/25/2022
Ms. Phaedra ChrousosIndependent Director240.74K----42female04/25/2022
Ms. Anne Sempowski WardIndependent Director243.24K----50female04/25/2022
Mr. Stephen Ray MitchellIndependent Director230.74K----70male04/25/2022
Company Overview More
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company’s marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company’s products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
CEO: Polymeropoulos M.D., Mihael H.
Market: NASDAQ
Hot List
SymbolLatest price%Chg